EE
MDGL icon

EWG Elevate’s Madrigal Pharmaceuticals MDGL Stock Holding History

EWG Elevate’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-500
Closed -$145K – 474
2022
Q4 		$145K Buy
+500
New +$48.9K 0.07% 89
2020
Q2 		– Sell
-11,086
Closed -$740K – 69
2020
Q1 		$740K Buy
11,086
+3,876
+54% +$323K 0.56% 35
2019
Q4 		$657K Buy
+7,210
New +$699K 0.36% 48

Other funds holding MDGL

ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.56% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $2.05B AUM 161.37% 1-Year Est. Return

EWG Elevate's MDGL Position: Q1 2023 in Review

EWG Elevate sold out of Madrigal Pharmaceuticals (MDGL) in Q1 2023, closing a stake of 500 shares — an estimated $145K sold.

EWG Elevate first reported a position in MDGL in Q4 2019 and held it in 3 quarters. The position peaked at $740K in Q1 2020. 223 funds tracked by Wall St. Rank hold MDGL as of Q1 2023.

  • EWG Elevate reported no remaining Madrigal Pharmaceuticals position as of Q1 2023 after selling out during the quarter.
  • EWG Elevate sold 500 Madrigal Pharmaceuticals shares in Q1 2023, an estimated $145K.
  • EWG Elevate first reported a position in Madrigal Pharmaceuticals in Q4 2019 and held it in 3 quarters.
  • EWG Elevate's Madrigal Pharmaceuticals position peaked at $740K in Q1 2020.
  • 223 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2023.

Based on EWG Elevate's 13F filing for Q1 2023, filed 13 Apr 2023.